Novel antiarrhythmic drugs in atrial fibrillation: focus on tedisamil

Suresh Krishnamoorthy, Gregory Lip

Research output: Contribution to journalArticle

5 Citations (Scopus)


BACKGROUND: Even established and effective antiarrhythmic drugs (AADs) in atrial fibrillation (AF) are limited by their pro-arrhythmic and non-target organ side effects. Therefore the search continues for safer and effective new AADs. OBJECTIVE: This review will examine a novel AAD, tedisamil--a multichannel potassium channel blocker--and its antiarrhythmic properties, focusing on AF. METHODS: Review of the literature and studies assessing the effect of tedisamil in humans and animal models with atrial arrhythmia(s). CONCLUSION: Tedisamil appears to be effective for rhythm restoration in acute-onset AF patients. The proven anti-ischemic effect with tedisamil may be an added benefit. Further studies with tedisamil are needed to confirm its safety and long-term efficacy.
Original languageEnglish
Pages (from-to)1191-6
Number of pages6
JournalExpert opinion on investigational drugs
Issue number8
Publication statusPublished - 1 Aug 2009


Dive into the research topics of 'Novel antiarrhythmic drugs in atrial fibrillation: focus on tedisamil'. Together they form a unique fingerprint.

Cite this